Severe COVID-19 in patients with hematological cancers presenting with viremia

J. M. Michot; T. Hueso; N. Ibrahimi; F. Pommeret; C. Willekens; E. Colomba; S. Francis; A. Bayle; P. H. Cournède; M. Merad; S. Foulon; L. Albiges; B. Gachot; F. Barlesi; J. C. Soria; V. Ribrag; F. Griscelli

doi:10.1016/j.annonc.2021.07.002

Severe COVID-19 in patients with hematological cancers presenting with viremia

J. M. Michot, T. Hueso, N. Ibrahimi, F. Pommeret, C. Willekens, E. Colomba, S. Francis, A. Bayle, P. H. Cournède, M. Merad, S. Foulon, L. Albiges, B. Gachot, F. Barlesi, J. C. Soria, V. Ribrag, F. Griscelli

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

9 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1297-1300
Nombre de pages	4
journal	Annals of Oncology
Volume	32
Numéro de publication	10
Les DOIs	https://doi.org/10.1016/j.annonc.2021.07.002
état	Publié - 1 oct. 2021
Modification externe	Oui

Accès au document

10.1016/j.annonc.2021.07.002

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Michot, J. M., Hueso, T., Ibrahimi, N., Pommeret, F., Willekens, C., Colomba, E., Francis, S., Bayle, A., Cournède, P. H., Merad, M., Foulon, S., Albiges, L., Gachot, B., Barlesi, F., Soria, J. C., Ribrag, V., & Griscelli, F. (2021). Severe COVID-19 in patients with hematological cancers presenting with viremia. Annals of Oncology, 32(10), 1297-1300. https://doi.org/10.1016/j.annonc.2021.07.002

@article{17c0ee5320fe4daea8a79b9057438174,

title = "Severe COVID-19 in patients with hematological cancers presenting with viremia",

author = "Michot, {J. M.} and T. Hueso and N. Ibrahimi and F. Pommeret and C. Willekens and E. Colomba and S. Francis and A. Bayle and Courn{\`e}de, {P. H.} and M. Merad and S. Foulon and L. Albiges and B. Gachot and F. Barlesi and Soria, {J. C.} and V. Ribrag and F. Griscelli",

note = "Funding Information: None declared. JMM reports outside of the submitted work, sponsorship for research at the Gustave Roussy Cancer Centre from AbbVie, Agios, Amgen, Astex, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Forma, Genentech, GlaxoSmithKline, H3 Biomedicine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, MedImmune, MSD, Novartis, Oncopeptides, Roche, Sanofi, Taiho and Xencor as well as personal fees, travel grants or advisory board fees from Astex, iQone, Mundipharma and Bristol Myers Squibb. LA reports outside of the submitted work, receiving consulting fees from Pfizer, Novartis, Bristol Myers Squibb, Ipsen, Roche, MSD, AstraZeneca, Merck, Amgen, Astellas, Exelixis, Corvus Pharmaceuticals and Peloton Therapeutics. FB reports outside of the submitted work, receiving personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda. VR reports outside of the submitted work, receiving sponsorship for research at the Gustave Roussy Cancer Centre from AbbVie, Agios, Amgen, Astex, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Forma, Genentech, GlaxoSmithKline, H3 Biomedicine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, MedImmune, MSD, Novartis, Oncopeptides, Roche, Sanofi, Taiho and Xencor as well as personal fees, travel grants or advisory board fees from Astex, iQone, Mundipharma and Bristol Myers Squibb. All other authors have declared no conflicts of interest.",

year = "2021",

month = oct,

day = "1",

doi = "10.1016/j.annonc.2021.07.002",

language = "English",

volume = "32",

pages = "1297--1300",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "10",

}

Michot, JM, Hueso, T, Ibrahimi, N, Pommeret, F, Willekens, C, Colomba, E, Francis, S, Bayle, A, Cournède, PH, Merad, M, Foulon, S, Albiges, L, Gachot, B, Barlesi, F, Soria, JC, Ribrag, V & Griscelli, F 2021, 'Severe COVID-19 in patients with hematological cancers presenting with viremia', Annals of Oncology, VOL. 32, Numéro 10, p. 1297-1300. https://doi.org/10.1016/j.annonc.2021.07.002

TY - JOUR

T1 - Severe COVID-19 in patients with hematological cancers presenting with viremia

AU - Michot, J. M.

AU - Hueso, T.

AU - Ibrahimi, N.

AU - Pommeret, F.

AU - Willekens, C.

AU - Colomba, E.

AU - Francis, S.

AU - Bayle, A.

AU - Cournède, P. H.

AU - Merad, M.

AU - Foulon, S.

AU - Albiges, L.

AU - Gachot, B.

AU - Barlesi, F.

AU - Soria, J. C.

AU - Ribrag, V.

AU - Griscelli, F.

N1 - Funding Information: None declared. JMM reports outside of the submitted work, sponsorship for research at the Gustave Roussy Cancer Centre from AbbVie, Agios, Amgen, Astex, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Forma, Genentech, GlaxoSmithKline, H3 Biomedicine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, MedImmune, MSD, Novartis, Oncopeptides, Roche, Sanofi, Taiho and Xencor as well as personal fees, travel grants or advisory board fees from Astex, iQone, Mundipharma and Bristol Myers Squibb. LA reports outside of the submitted work, receiving consulting fees from Pfizer, Novartis, Bristol Myers Squibb, Ipsen, Roche, MSD, AstraZeneca, Merck, Amgen, Astellas, Exelixis, Corvus Pharmaceuticals and Peloton Therapeutics. FB reports outside of the submitted work, receiving personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda. VR reports outside of the submitted work, receiving sponsorship for research at the Gustave Roussy Cancer Centre from AbbVie, Agios, Amgen, Astex, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Forma, Genentech, GlaxoSmithKline, H3 Biomedicine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, MedImmune, MSD, Novartis, Oncopeptides, Roche, Sanofi, Taiho and Xencor as well as personal fees, travel grants or advisory board fees from Astex, iQone, Mundipharma and Bristol Myers Squibb. All other authors have declared no conflicts of interest.

PY - 2021/10/1

Y1 - 2021/10/1

UR - http://www.scopus.com/inward/record.url?scp=85114374371&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.07.002

DO - 10.1016/j.annonc.2021.07.002

M3 - Letter

C2 - 34265373

AN - SCOPUS:85114374371

SN - 0923-7534

VL - 32

SP - 1297

EP - 1300

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -